Sign in

Josh Osowicki

@joshosowicki.bsky.social
668 followers 1.2K following 115 posts
PostsRepliesMedia
Reposted by Josh Osowicki
1Day Sooner @1daysooner.bsky.social · 18/09/2026
HHS's Office of Inspector General asked whether federal fraud and abuse law is making it harder than it should be to pay clinical trial participants fairly.
111
Reposted by Josh Osowicki
CMI Communications @cmicomms.bsky.social · 17/09/2026
📣 New #Communicable / #Breakpoints drops Mon 21 Sep! Erin McCreary, PharmD & Josh Davis are joined by Steve Webb & Steven Tong to discuss REMAP-CAP results suggesting that oseltamivir may harm critically ill patients, while also highlighting the importance and impact of RCTs. #IDSky #ViroSky #flu
0127
Reposted by Josh Osowicki
bridges2develop.bsky.social @bridges2develop.bsky.social · 25/08/2026
📢 Abstract submissions are open for the First Global Strep A Vaccine Conference! Deadline- September 7, 2026! Original research, data & innovations welcome. Hope to see you in Kuala Lumpur in Feb 2027. Full details on our website: www.globalstrepavax.org #GSAVConference2027 #StrepA #GlobalHealth
globalstrepavax.org
Global Strep A Vaccine Conference
The First Global Strep A Vaccine Conference. Bringing great science to global impact: Fast-tracking Strep A vaccine development
011
Reposted by Josh Osowicki
Katharine Collins @kat-a-collins.bsky.social · 17/07/2026
📣Exciting announcement 📣 The First Global Strep A Vaccine Conference Call for abstracts will open soon! 🌏Venue update: Kuala Lumpur, Malaysia, first week of February 2027 📝Abstract submissions open 30 July 2026. #GSAVConference2027 Read the full announcement here ⬇️ lnkd.in/eiu95fXm
0125
Reposted by Josh Osowicki
Michael Marks @drmichaelmarks.bsky.social · 17/06/2026
Excited 1st SNAP result out @thelancet.com PSSA: Fluclox v BenPen thelancet.com/journals/lancet/article/PIIS0140-6736(26)00761-0/fulltext @nejm.org MSSA: Fluclox v Cefazolin nejm.org/doi/full/10.1056/NEJMoa2506905 Should change practice globally Privilege to help deliver trial with fantastic team
helancet.com
1208
Reposted by Josh Osowicki
Jonathan Ryder, MD @jonathanrydermd.bsky.social · 11/06/2026
Excited to share an article that I've long awaited to share seeking to answer: What is the right dose of cephalexin/cefadroxil for SSTIs? We reviewed clinical studies & conducted PTA sims to elucidate this #IDSky @absteward.bsky.social accpjournals.onlinelibrary.wiley.com/doi/10.1002/...
accpjournals.onlinelibrary.wiley.com
Getting It Right the Second Time: How Can we Optimize First‐Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?
Optimal cephalexin and cefadroxil dosing for skin and soft tissue infections (SSTIs) is unclear. We summarize clinical and pharmacokinetic/pharmacodynamic (PK/PD) data that compare dosing strategies ...
73515
Reposted by Josh Osowicki
Rossana Rosa @drrossanarosa.bsky.social · 05/06/2026
If Strep pyogenes had a walk up song (thought brought about by the most recent Breakpoints episode 🔥🧫) @sidpharm.bsky.social @joshosowicki.bsky.social podcasts.apple.com/us/podcast/b... #IDSky #MedSky #PharmSky open.spotify.com/track/0jfIKx...
open.spotify.com
Firestarter
The Prodigy · The Fat of the Land · Song · 1997
2114
Reposted by Josh Osowicki
Society of Infectious Diseases Pharmacists - SIDP @sidpharm.bsky.social · 05/06/2026
🆕 Episode of #Breakpoints GAS infections remain a global challenge. Dr. Shiranee Sriskandan, Dr. Josh Osowicki, and Dr. Tom Parks join host Dr. Erin McCreary to explore the evolving landscape of GAS. Tune in as we highlight practical pearls you can apply in your own practice. 🎧️ sidp.pinecast.co
373
Reposted by Josh Osowicki
Katharine Collins @kat-a-collins.bsky.social · 26/05/2026
Today, Coefficient Giving is launching the Strep A Vaccine Fund, a multi-donor initiative to accelerate vaccine development against one of the world's most neglected infectious diseases relative to its scale. Strep A kills ~639,000 people a year. There is no vaccine. I think that can change 🧵
12213
Reposted by Josh Osowicki
Society of Infectious Diseases Pharmacists - SIDP @sidpharm.bsky.social · 08/05/2026
The Society of Infectious Diseases Pharmacists and ESCMID are excited to release a new Breakpoints episode: ESCMID Global Trials: PETER PEN and ASTARTE Check it out!
074
Reposted by Josh Osowicki
Brad Spellberg @bradspellberg.bsky.social · 21/01/2026
0 reason to think things would be difft in non HIV, children, xenomorphs, non carbon based life forms, or any other excuses stubborn deniers have. My suggestion? Do some yoga. Meditate. Light incense. Relax. And stop torturing your patients with 2 weeks of amphoterrible. Subtle as always, I know.
322
Reposted by Josh Osowicki
Dr. D Boulware, MD MPH @drboulware.bsky.social · 21/01/2026
Is It Time to Use Single-Dose Amphotericin B for HIV-Related Cryptococcal Meningitis in the USA? The answer is yes! doi.org/10.1001/jama...
doi.org
Single-Dose Amphotericin B for HIV-Related Cryptococcal Meningitis
Cryptococcal meningitis remains a life-threatening opportunistic infection among people with advanced HIV, even in high-resource settings. For decades, the standard induction regimen in the United Sta...
52311
Reposted by Josh Osowicki
ᐯIᑕTOᖇ ᑎIᘔET, ᗰᗪ @nizet.bsky.social · 20/01/2026
Pleased to share our brief commentary on how antiplatelet drugs such as ticagrelor (Brilinta) may have an intriguing beneficial action toward effective treatment of Staphylococcus aureus bacteremia and endovascular infection #drugrepurposing
tandfonline.com
Bridging specialties: repurposing platelet drugs prescribed by cardiologists to help infectious disease doctors treat Staphylococcus aureus bacteremia
The platelet is the most important cell in the bloodstream in providing endovascular immunity against Staphylococcus aureus bacteremia. Both quantitative and qualitative thrombocytopenia have been ...
252
Reposted by Josh Osowicki
ᐯIᑕTOᖇ ᑎIᘔET, ᗰᗪ @nizet.bsky.social · 12/01/2026
From first hand clinical experience, meningococcal sepsis and meningitis are indelibly etched in my mind—diseases that can progress rapidly from flu-like symptoms to loss of life or limb—even in previously health children & young adults Vaccination had reduced rates up to 90% – don't give up now
nbcnews.com
As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
Under Robert F. Kennedy Jr.’s guidance, the CDC no longer recommends routine vaccination to protect against meningococcal disease.
0132
Reposted by Josh Osowicki
Steven Tong @steventong.bsky.social · 12/01/2026
Pretty cool that Robin Patel picks Ouli Xie's @lancetmicrobe.bsky.social paper on SDSE and S pyogenes as one of her top 3 clinical microbiology papers for 2025! As expected, Robin does a great job explaining the paper. www.thelancet.com/journals/lan... @onisillos.bsky.social
thelancet.com
Invasive Streptococcus dysgalactiae subspecies equisimilis compared with Streptococcus pyogenes in Australia, 2011–23, and the emergence of a multi-continent stG62647 lineage: a retrospective clinical...
We identified a substantial burden of invasive SDSE, dominated by the emergent stG62647 lineage. The contrasting epidemiology between species in the different Australian regions, during COVID-19 NPIs,...
2157
Reposted by Josh Osowicki
Ben Morton @benmorton.bsky.social · 03/01/2026
How can we accelerate human trials of vaccines, therapeutics and diagnostics against priority pathogens in advance of epidemics and pandemics? Well, if we can identify safe, weakened versions controlled human infection model trials might be possible: journals.plos.org/plosntds/art... 🧪 🩺 #IDsky
journals.plos.org
Attenuated viral strains of priority pathogens for potential use in controlled human infection model studies: A scoping review
Author summary There are several families of viruses that scientists predict are most likely to cause a future pandemic, such as coronaviruses or Ebola. Studying these viruses ahead of time might mean...
1227
Reposted by Josh Osowicki
1Day Sooner @1daysooner.bsky.social · 15/12/2025
1/2 Progress in vaccine development only happens when people are willing to step up. Challenge trials are one of the most powerful tools we have for speeding lifesaving vaccines. If we want faster, more equitable global health outcomes, we need to expand and support this research model.
111
Reposted by Josh Osowicki
Michael Marks @drmichaelmarks.bsky.social · 02/12/2025
Congratulations to Burrell St Sexual Health: First UK patient into SOS Global - Evaluating mucosal shedding of spirochetes in heterosexual individuals with syphilis. Great collaboration led by Melbourne Sexual Health Centre focused on understanding syphilis transmission.
The Study Logo which says SOS Global superimposed on a picture of a globe with some spirochetes of syphilis on it.
041
Reposted by Josh Osowicki
NEJM.org @nejm.org · 31/10/2025
In a trial in healthy U.K. adults who were challenged with S. Paratyphi A in a controlled human infection model, two doses of the candidate vaccine CVD 1902 led to protection against S. Paratyphi A infection. Full VASP phase 2b trial results: nej.md/3Lypfd5 #MedSky #IDSky
Kaplan–Meier curves for a diagnosis after challenge with S. Paratyphi A in a controlled human infection model.
173
Reposted by Josh Osowicki
Steven Tong @steventong.bsky.social · 27/10/2025
Want to come work on SNAP, BALANCE+, and STRAP? And change how we treat and manage bloodstream infections? See below. #IDSky
095
Reposted by Josh Osowicki
aamri.bsky.social @aamri.bsky.social · 15/10/2025
AAMRI is thrilled to announce our 2025 AAMRI Rising Star Award Finalists, proudly sponsored by CSL. These outstanding researchers are shaping the future of health + medical research in Australia 👏 #2025AAMRIRisingStar aamri.org.au/news-events/... Winner announced 4 Nov at #2025AAMRIConvention
aamri.org.au
AAMRI announces 2025 Rising Star finalists showcasing our brightest young researchers - AAMRI
AAMRI is delighted to announce the finalists for the 2025 AAMRI Rising Star Award, proudly sponsored by CSL. The award shines a spotlight on the extraordinary talent driving the future of health and m...
111
Reposted by Josh Osowicki
Fabian Kong @fabysk.bsky.social · 06/10/2025
I am exciting to publish our validated, lab-based model of oral gonorrhoea infection! With this model we can begin to understand how gonorrhoea behaves in the mouth (which is lacking) and screen for new compounds for interventions such as a gum to prevent infections. sti.bmj.com/content/earl...
sti.bmj.com
021
Reposted by Josh Osowicki
ᐯIᑕTOᖇ ᑎIᘔET, ᗰᗪ @nizet.bsky.social · 23/08/2025
Our new review “𝘛𝘩𝘦 𝘊𝘦𝘯𝘵𝘳𝘢𝘭 𝘐𝘮𝘱𝘰𝘳𝘵𝘢𝘯𝘤𝘦 𝘰𝘧 𝘝𝘢𝘤𝘤𝘪𝘯𝘦𝘴 𝘵𝘰 𝘔𝘪𝘵𝘪𝘨𝘢𝘵𝘦 𝘵𝘩𝘦 𝘛𝘩𝘳𝘦𝘢𝘵 𝘰𝘧 𝘈𝘯𝘵𝘪𝘣𝘪𝘰𝘵𝘪𝘤-𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘉𝘢𝘤𝘵𝘦𝘳𝘪𝘢𝘭 𝘗𝘢𝘵𝘩𝘰𝘨𝘦𝘯𝘴” is out Compared to antibiotics, vaccines: ✓ Act prophylactically at low pathogen burden ✓ Less prone to inducing resistance due to multifactorial nature of immune pressure 🧵1/3
23113
Reposted by Josh Osowicki
Michael Marks @drmichaelmarks.bsky.social · 21/08/2025
Exited to announce 2 EDCTP consortiums led @lshtm.bsky.social w partners in Europe & West, East & Southern Africa MAMS4CL will deliver seamless Phase 2-3 trial of treatments for Cutaneous Leishmaniasis. IVMKIDS will provide data on paediatric dosing ivermectin down to 5kg/weight for STH & Scabies.
062
Reposted by Josh Osowicki
Michael Marks @drmichaelmarks.bsky.social · 08/08/2025
Phenomenal piece of work by a great team across @mrcunitgambia.bsky.social @lshtm.bsky.social @sheffielduni.bsky.social - Delighted to have played a small part in combining epidemiology & immunology to shed light on what protection for #StrepA might look like & help advance vaccine development.
061
Reposted by Josh Osowicki
Claire Turner @claireyt.bsky.social · 08/08/2025
Fantastic to see this immense body of excellent work published! Well done @alexjkeeley.bsky.social and everyone involved 👏 #StrepA @floreyinstitute.bsky.social @molmicrosheffield.bsky.social
052
Reposted by Josh Osowicki
Thushan de Silva @thushan-desilva.bsky.social · 08/08/2025
VERY excited by our latest work on StrepA below, but also rhe multiple collaborations and work to come off the back of this at MRCG
0111
Reposted by Josh Osowicki
Alex Keeley @alexjkeeley.bsky.social · 08/08/2025
🧵 Our paper out today in @naturemedicine.bsky.social www.nature.com/articles/s41... On development of #StrepA #Immunity over life course in #TheGambia raising hope for #vaccines on the horizon 1/ #Immunosky #IDsky #MicroSky #globalhealth.
nature.com
33511
Reposted by Josh Osowicki
Andrew S. MacDonald @profandrewmac.bsky.social · 28/07/2025
A real pleasure to be a part of this beautiful new study on T cell responses in repeat controlled human infection vs natural infection with #schistosomes, spearheaded by @emmahoulder.bsky.social with many wonderful colleagues #helminths #ImmunoSky #IDSky 🪱 🧪 www.nature.com/articles/s41...
nature.com
T cell responses in repeated controlled human schistosome infection compared to natural exposure - Nature Communications
In schistosomiasis-endemic regions, the cyclical nature of infection and treatment complicates understanding of host immune responses. Repeated controlled human Schistosoma mansoni infection, designed...
0104
Reposted by Josh Osowicki
ᐯIᑕTOᖇ ᑎIᘔET, ᗰᗪ @nizet.bsky.social · 26/07/2025
Congratulations to 𝐃𝐎𝐂𝐓𝐎𝐑 𝐃𝐀𝐍𝐈𝐄𝐋 𝐒𝐔𝐍 on the successful defense of his PhD "𝘊𝘰𝘯𝘴𝘪𝘥𝘦𝘳𝘪𝘯𝘨 𝘵𝘩𝘦 𝘏𝘰𝘴𝘵-𝘗𝘢𝘵𝘩𝘰𝘨𝘦𝘯 𝘐𝘯𝘵𝘦𝘳𝘧𝘢𝘤𝘦 𝘧𝘰𝘳 𝘕𝘰𝘷𝘦𝘭 𝘈𝘱𝘱𝘳𝘰𝘢𝘤𝘩𝘦𝘴 𝘵𝘰 𝘛𝘳𝘦𝘢𝘵 𝘋𝘳𝘶𝘨 𝘙𝘦𝘴𝘪𝘴𝘵𝘢𝘯𝘵 𝘚𝘵𝘢𝘱𝘩𝘺𝘭𝘰𝘤𝘰𝘤𝘤𝘶𝘴 𝘢𝘶𝘳𝘦𝘶𝘴" in the Biomedical Sciences Graduate Program as part of his dual degree training in the UCSD SSPPS PharmD/PhD Program
0423
Reposted by Josh Osowicki
Paul Sax @paulsaxmd.bsky.social · 18/07/2025
Thanks for the reference! And of course there's this classic from @tonybreu.bsky.social x.com/tony_breu/st...
x.com
Tony Breu on X: "1/ Why hasn't syphilis developed resistance to penicillin (PCN)? It took staph aureus about a year to demonstrate resistance. After 75 years, there has never been a reported case of treponema pallidum resistant to PCN. Let’s have a look at why this might be..." / X
1/ Why hasn't syphilis developed resistance to penicillin (PCN)? It took staph aureus about a year to demonstrate resistance. After 75 years, there has never been a reported case of treponema pallidum resistant to PCN. Let’s have a look at why this might be...
011
Reposted by Josh Osowicki
Michael Marks @drmichaelmarks.bsky.social · 06/07/2025
Latest from @mrcunitgambia.bsky.social #StrepA group. Show clinical decision rules developed elsewhere (mostly HIC) have poor performance in Gambia & molecular tests detect far more #StrepA than culture. Given burden of RhD in Africa we urgently need better & affordable tests for #StrepA diagnosis
journalofinfection.com
Evaluating clinical decision rules and rapid diagnostic tests for the diagnosis of Streptococcus pyogenes pharyngitis in Gambian children: a diagnostic accuracy study
Accurate diagnosis of Streptococcus pyogenes (S. pyogenes) pharyngitis is imperative in high rheumatic heart disease-burden countries. We aimed to assess the diagnostic accuracy of two rapid diagnosti...
053
Reposted by Josh Osowicki
Ben Morton @benmorton.bsky.social · 02/07/2025
RSV and pneumococcus demonstrate close interaction in epidemiological studies but which is 🐥 and which is 🥚. This study by our group is designed to find out... #idsky #medsky journals.plos.org/plosone/arti...
journals.plos.org
Understanding the interaction of upper respiratory tract infection with respiratory syncytial virus and Streptococcus pneumoniae using a human challenge model: a multicenter, randomized controlled stu...
Background Streptococcus pneumoniae (pneumococcus) and respiratory syncytial virus (RSV) are major causes of respiratory infections globally. Viral and bacterial co-infections are commonly observed in...
062
Reposted by Josh Osowicki
Alexander V. Veselov 😷🎮 @alexxxmd.bsky.social · 02/07/2025
A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge. Kitson, G., Byford, M., Cass, L. et al. Infect Dis Ther (2025). doi.org/10.1007/s401...
doi.org
A Phase II, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of HEX17, a Novel Broad-Spectrum Antiviral Drug, in a Controlled Human Infection Model of Influenza Challenge - ...
Introduction Viral respiratory tract infections are of global concern, with an unmet need for a broad-spectrum antiviral prophylactic. HEX17, a multivalent carbohydrate-binding module, binds to sialic...
011
Reposted by Josh Osowicki
Michael Marks @drmichaelmarks.bsky.social · 24/06/2025
Come & work with me @benvyle.bsky.social @lshtm.bsky.social & @thelovetankcic.bsky.social Research Assistant with funded PhD within multidisciplinary project on Syphilis & STI control in the UK. Working with us to understand stakeholder & community perspectives on novel STI control strategies
jobs.lshtm.ac.uk
Job Opportunity at LSHTM: Research Assistant
The London School of Hygiene & Tropical Medicine (LSHTM) is one of the world’s leading public health universities. Our mission is to improve health and health equity in the UK and worldwide; working i...
11513
Reposted by Josh Osowicki
British Infection Association @biainfection.bsky.social · 22/06/2025
Read the latest Journal of #Infection for the Phase-IIa trial and how it evaluates the safety and pharmacokinetics of high-dose, 10 weekly subcutaneous injections of penicillin (#SCIP) in young people with a history of acute rheumatic fever (#ARF) 👉 www.journalofinfecti...
123
Reposted by Josh Osowicki
ᐯIᑕTOᖇ ᑎIᘔET, ᗰᗪ @nizet.bsky.social · 14/06/2025
🄰🅆🄴🅂🄾🄼🄴 Stubbusch et al 𝘚𝘊𝘐𝘌𝘕𝘊𝘌 Bacteria 🦠 repurpose Type VI Secretion Systems based on environmental cues: Nutrient-rich environments ➜ kill competitors Under starvation ➜ lyse neighbors to scavenge their nutrients Even “non-pathogens” shift from competition to predation as a survival strategy
science.org
Antagonism as a foraging strategy in microbial communities
In natural habitats, nutrient availability limits bacterial growth. We discovered that bacteria can overcome this limitation by acquiring nutrients by lysing neighboring cells through contact-dependen...
22912
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 05/06/2025
Dr O Xie has an entertaining talk on S. dys subsp eq [SDSE] 🐴 iSDSE has similar incidence and mortality v iGAS 🐎 Less genomic clustering in SDSE 🫏 Global dissemination iSDSE driven by stG62647-lineage #LISSSD25 #clinmicro #idsky
131
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 05/06/2025
Last of the #LISSSD25 presentations is Prof Victor Nizet imploring the community to think like streptococci in these times of authoritarianism USA anti-science 🍇 Evade host immunity (cont to do work) 🍇 Form biofilms (network) 🍇 Colonise diverse hosts (expand skill sets) #strep #idsky
222
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 05/06/2025
I said no more #LISSSD25 posts but forgot a major highlight! Most sessions started w/ a patient lived experience video, and you can see them all @ lisssd2025.org/patient-stories Looking after patients during thier illnesses is v. stressful so it's great to hear their experiences when recovered.
lisssd2025.org
Patient Stories — LISSSD 2025
054
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 04/06/2025
Prof N Moreland from NZ speaks through the ARF perturbed immune response in ARF. 🌍 All strep A serotypes assoc w/ ARF in NZ 🌍 Increased IgG3 ab phenotpes 🌍 Immune infiltration valves incl plasma cells. 🌍 DIifferences in immue activation in acute & chronic RHD #LISSSD25
152
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 05/06/2025
Dr K Gibney flys the flag for 🦘 clin trials by 🎺 ISAAC 🔎 at Abx prophylaxis of close iGAS contacts (enrolling soon) STRAP 🔎 backbone Abx, adjunctive Abx, and IVIg (enrolling 2026ish) Only enrolling in Aus for now but looking for int. collab. #LISSSD25 #idsky #clinicaltrials #strep
234
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 05/06/2025
Prof M Good & A/Prof M Pandey close #LISSSD25 thanking all the local committee, scientific advisory committee (led by Dr T Lamagni & @joshosowicki.bsky.social), presenters, and delegates. Prof A Steer announces #LISSSD28 is to be held in 📌 Limassol, Cyprus 🇨🇾 2028
052
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 03/06/2025
Dr J Hart & team on validating clinical decision rules for strep throat: 🌹 Fiji rule (sore throat & neither coryza or hoarseness) is no better than chance. 🚫 No other algorithm tested is any better! Underscores urgent need for POC diagnostics in these settings. #LISSSD25 #idsky
042
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 03/06/2025
Prof M Good from Griffith reports some cool unpub phase I vaccine data from two vaccine candidates (J8/S2 & P*17/S2) 💉 Both protect in 🐁 💉 Induce ab response in🚶‍♂️ 💉 Wanes after 6 months, BUT 💉 Opsonic killing increases after 6m #LISSSD25 #strepA #idsky
032
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 03/06/2025
More cool penicillin data - A/Prof J Bennett presents NZ data for subcut BenPen for RHD/ARF 💉 Penicillin >20ng/mL for 56d & >10ng/mL for 70d 💉 Worked better in ⬆️ BMI 💉 No breakthrough infections 😊 Highly accepted - only 1 pt switched back to IM BenPen #LISSSD25 #idsky
143
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 03/06/2025
A/Prof Laurens Manning presents a human challenge study looking to define penicillin MIC to prevent strep throat. 💊 ~9ng/mL penicillin (lower then standard threshold 20ng/mL) prevents clinical strep throat and systemic inflammation as measured by CRP. #LISSSD25 #idsky
143
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 02/06/2025
Prof A Steer speaks about the progress to a Strep A vaccine, and highlights the current Emm and non-emm candidates as well as the challenges in Strep A. Steer highlights new human challenge models, published trial complication guidelines and monitoring, and building momenum. #LISSSD25 #idsky
042
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 02/06/2025
Prof de Silva & Dr Keeley speak on Strep A epi & immunity in the Gambia. 🗝️ Hyperendemicity of Strep A 🗝️ Index infections not explained by household contacts 🗝️ Early life immunity develops <2 y/o 🗝️ Ab response to carriage & infection 🗝️ ?protective immunity from SLO, SpyAD, SpyCEP #LISSSD25 #IDsky
356
Reposted by Josh Osowicki
Stuart Campbell @sc345.bsky.social · 02/06/2025
Dr A Seale of the Gates foundation talks about the burden of and difficulties of understanding it in GBS worldwide, but of even the likely under estimates suggest 1billion USD yearly benefits of a vaccine. She then links the successful RSV vaccine as a model for a possible GBS. #LISSSD25 #idsky #gbs
021